Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Market Cap 11.06B 9.56B 8.81B 8.26B 15.43B 1,054B 15.71B 105B 40.56B 510B 41.51B 40.61B 1,772B P/E ratio 2026 *
25.7x
P/E ratio 2027 * 20x
Enterprise value 11.14B 9.63B 8.88B 8.32B 15.54B 1,062B 15.82B 105B 40.86B 514B 41.81B 40.91B 1,785B EV / Sales 2026 *
3.35x
EV / Sales 2027 * 2.73x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day+5.35%
1 week+12.06%
Current month+10.12%
1 month+3.54%
3 months-33.60%
6 months-45.75%
Current year-43.85%
1 week 144.27
Extreme 144.2701
160.87
1 month 140.63
Extreme 140.63
160.87
Current year 140.63
Extreme 140.63
299.8
1 year 140.63
Extreme 140.63
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
06-03Buy

Director

2,790 0.0040%
06-03Sell

Director

-418 0.0006%
06-03Buy

Director

3,450 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
+5.35%+12.06%-47.78%-43.62% 10.49B
+0.83%+4.92%-31.60%-10.27% 158B
+1.60%+11.16%-6.26%-2.09% 104B
+2.00%+5.56%-1.54%+56.87% 53.33B
-0.33%-7.18%+49.90%+46.37% 52.82B
+2.08%+5.27%-11.87%-39.55% 41.33B
+2.05%+6.45%-8.74%-37.12% 29.57B
+6.54%+8.50% - - 28.58B
+4.66%+7.20%+49.56%-3.91% 22.59B
-0.11%+0.11%-13.64%+2.17% 21.03B
Average +2.47%+4.60%-2.44%-3.46% 52.1B
Weighted average by Cap. +1.69%+5.06%-7.09%+0.84%

Financials

2026 *2027 *
Net sales 3.32B 2.87B 2.65B 2.48B 4.64B 317B 4.72B 31.42B 12.19B 153B 12.48B 12.21B 533B 3.94B 3.41B 3.14B 2.94B 5.5B 376B 5.6B 37.26B 14.46B 182B 14.8B 14.48B 632B
Net income 432M 374M 344M 323M 603M 41.2B 614M 4.09B 1.59B 19.93B 1.62B 1.59B 69.25B 567M 490M 452M 423M 790M 54.02B 805M 5.36B 2.08B 26.13B 2.13B 2.08B 90.79B
Net Debt 80.64M 69.75M 64.27M 60.24M 113M 7.69B 115M 762M 296M 3.72B 303M 296M 12.92B -289M -250M -230M -216M -403M -27.53B -410M -2.73B -1.06B -13.32B -1.08B -1.06B -46.28B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
09/06/26 159.61 $ +5.35% 1,819,970
08/06/26 151.51 $ -1.12% 1,569,646
05/06/26 153.22 $ +4.65% 2,307,440
04/06/26 146.41 $ +2.17% 1,410,455
03/06/26 143.30 $ +0.61% 1,140,980
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
159.61USD
Average target price
243.78USD
Spread / Average Target
+52.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW